Lonza to Supply Commercial Volumes of Antibody Drug

Lonza has disclosed that GlaxoSmithKline (GSK) and Genmab’s antibody drug Arzerra, for treating chronic lymphocytic leukemia (CLL), will be manufactured by Lonza. Arzerra, also known as ofatumumab, is a monoclonal antibody. The drug recently has been approved by the U.S. FDA. Lonza carried out process development and cGMP manufacturing services associated with the production of the drug. Lonza says it will supply the drug under the terms of a long-term supply agreement. Financial details were not disclosed.   Some analysts suggest sales of the drug for...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers